We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2023

Session Item

Sunday
May 14
09:00 - 10:00
Business Suite 1-2
Head & neck
Jon Cacicedo, Spain
Poster Discussion
Clinical
Management of 80 Sinonasal Undifferentiated Carcinomas. A french retrospective multicentre study
Pierre Pouvreau, France
PD-0395

Abstract

Management of 80 Sinonasal Undifferentiated Carcinomas. A french retrospective multicentre study
Authors:

Pierre Pouvreau1, Julien Coelho2, Cécile Rumeau3, Olivier Malard4, Renaud Garrel5, Juliette Thariat6, Noémie Vulquin7, Claire Castain8, Ludovic de Gabory9, Charles Dupin1

1Bordeaux University Hospital, Department of Radiation Oncology, Bordeaux, France; 2Bordeaux university, SANPSY unit, UMR 6033, Bordeaux, France; 3Nancy University Hospital, Department of Head and Neck Surgery, Nancy, France; 4Nantes University Hospital, Department of Head and Neck Surgery, Nantes, France; 5Montpellier University Hospital, Department of Head and Neck Surgery, Montpellier, France; 6François Baclesse center, Department of Radiation Oncology, Caen, France; 7Georges François Leclerc Center, Department of Radiation Oncology, Dijon, France; 8Bordeaux University Hospital, Department of histopathology, Bordeaux, France; 9Bordeaux University Hospital, Department of Head and Neck Surgery, Bordeaux, France

Show Affiliations
Purpose or Objective

Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive disease requiring multimodal treatment, and multiple new entities once included in the spectrum of SNUC, such as SWI/SNF-deficient carcinomas, are emerging. We aimed to provide new data regarding the role of chemotherapy and surgery and the prognostic factors of disease-free survival.

Material and Methods

This study was based on data from the French Network of Rare Head and Neck Cancers database (REFCOR), and included patients with SNUC treated with curative intent from 2007 to 2021 across 22 centres in France. We collected data on treatments, histologic and oncologic outcomes, toxicities and prognostic factors.

Results

A total of 80 patients were included in the analysis. Among the entire cohort, the 5-year progression-free survival (PFS) and overall survival (OS) rates were 58% and 63%, respectively. Approximately 100% of the patients were treated with irradiation, 29% with surgery, 56% with neoadjuvant chemotherapy (82% had either a partial or a complete response) and 76% with chemoradiotherapy. No treatment modality was associated with a better OS or PFS, including surgery (p=0.34). There was a trend for a better PFS for the patients treated with chemotherapy (neoadjuvant or concurrent, p=0.062). The patients with SWI/SNF-deficient carcinomas had a significantly worse PFS (p=0.021) and OS (p=0.03) than the rest of the population.

Conclusion

In the management of localised SNUC among all patients treated with irradiation, surgery yielded no benefit, whereas the addition of chemotherapy tended to improve disease-free survival.